Dr. Khire worked for 10 years at a major pharmaceutical company, Bayer HealthCare. At Bayer, he was involved in the development of “Nexavar”, a first in class multi-kinase inhibitor which has been approved as a first line therapy for a treatment of kidney and liver cancers. In 2003, Dr. Khire founded Cheminpharma, LLC , a medicinal chemistry focused drug discovery services company. As a Chief Executive Officer of Cheminpharma, he delivered positive cash flow for straight three years and also successfully executed several business deals with biotech companies. Under his leadership, Cheminpharma’s team identified a novel, potent MEK kinase inhibitor CIP-1374. In 2010, he co-founded AlloMek Therapeutics which is geared towards the clinical development of MEK kinase inhibitors.
Dr. Barry Hart brings, to AlloMek, over 15 years of leadership experience at pharmaceutical and biotechnology companies. Most recently Barry was the Associate Director of Medicinal Chemistry at Medivation, Inc. For the past five years Barry has focused on building research organizations based on contract research organization (CRO) strategic partnerships. Barry has been responsible for identifying and partnering with CROs to advance pharmaceutical research programs from screening hit into development. Barry has successfully led programs in a variety of therapeutic areas: CNS (Medivation, Inc); anti-viral (ViroBay, Inc); kinase directed oncology and anti-fibrotic disorders (Scios and Johnson & Johnson); osteoporosis and oncology (Bayer Pharmaceuticals).